Tag Archive for: ADCs

Hot topic: Should Pharma be looking east for new assets?

“Go west, young man!”   Such was the famous advice of Horace Greeley, founder and editor of the (long defunct) New York Tribune, to an acquaintance, Josiah B. Grinnell, in the mid-19th century.  Countless individuals, businesses, and industries have since followed that advice – and gone on to strike gold.  But when it comes to where […]

Synaffix and Mitsubishi Tanabe Pharma Sign License Agreement for ADC Technology

License agreement centered around development of a single ADC program Usage of Synaffix GlycoConnect®, HydraSpace® and toxSYN® ADC technologies to enhance efficacy, tolerability and target engagement Amsterdam, The Netherlands, 9 January 2025 — Synaffix B.V. (“Synaffix”), a Lonza company (SWX:LONN) focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with […]

Boehringer Ingelheim broadens oncology portfolio with license for Synaffix’s ADC technology

Amsterdam, The Netherlands, Basel, Switzerland and Ingelheim, Germany, (9 January 2025) — Boehringer Ingelheim and Synaffix B.V. (“Synaffix”), a Lonza company (SWX:LONN) focused on commercializing its clinical-stage platform technology for the development of best-in-class antibody-drug conjugates (ADCs), today announced that Boehringer has licensed Synaffix’s ADC technology. This new partnership significantly bolsters Boehringer’s ADC portfolio, driven […]

Elevation Oncology Licenses ADC Technology from Synaffix to Drive Pipeline Expansion

Licensing agreement gives Elevation Oncology access to Synaffix’s ADC technology for one program in combination with SYNstatin E™ Elevation Oncology nominates a novel HER3 ADC candidate EO-1022 leveraging its antibody as well as Synaffix’s proprietary ADC development technologies AMSTERDAM, THE NETHERLANDS, 12 December 2024 — Synaffix B.V., a Lonza company (SIX:LONN) focused on commercializing its […]

Synaffix Licenses Metal-Free Click Chemistry Technology to Illumina for Next-Generation DNA Sequencing Applications

Agreement grants access to Synaffix patent portfolio related to metal-free click chemistry Technology to be used in Illumina’s next-generation sequencing (NGS) products AMSTERDAM, THE NETHERLANDS, 4 December 2024 — Synaffix B.V., a Lonza company (SIX:LONN) focused on commercializing its clinical-stage bioconjugation platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index and […]